Teva Announces Collaboration to Commercialize Formycon’s Biosimilar Candidate to Eylea® (aflibercept) in major parts of Europe and in Israel

Contributed by: GlobeNewswire

Tags

Biosimilars

More Like This

Celltrion Expands Biosimilar Portfolio in the European Union Following European Commission Approval of Two Biosimilars

Celltrion Receives Positive CHMP Opinion for Three Biosimilars in the European Union

Takeda Announces Third-Quarter FY2023 Results; On-Track Towards Full-Year Management Guidance With Strong Momentum in Growth & Launch Products

Incyte Gains Exclusive Global Development and Commercialization Rights to Tafasitamab (Monjuvi®)

Calliditas Therapeutics Presents Data at the 61st European Renal Association Congress

Incyte to Highlight Data From its Oncology Portfolio at the 2024 ASCO Annual Meeting and EHA2024 Congress

Biocytogen/Eucure Biopharma to Present Complete Clinical Data from YH003 (anti-CD40 mAb) Phase I Trial at ESMO 2023

Launch of Phase 3 clinical trial with Nefecon in Japan